Quanterix Recognized as a Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™

Nov 17, 2021

2021 marks fourth consecutive year Quanterix was recognized on the Deloitte Technology Fast 500

BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 17, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it has been recognized on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. This marks the fourth consecutive year Quanterix has been named to the Technology Fast 500.

“Being recognized by Deloitte is a testament to Quanterix’ mission of advancing the science of precision health, our incredible team and driving today’s healthcare revolution forward through plasma biomarker analysis,” said Kevin Hrusovsky, Chairman and CEO, Quanterix Corporation. “We support breakthrough advancements across most therapeutic areas to help the world’s top researchers combat some of our most significant diseases, including Alzheimer’s and COVID-19. Our Simoa® technology continues to advance the possibility of a future with earlier, more accessible, non-invasive disease detection that could lead to more effective treatment options and someday, to the prevention of disease.”

This year, Quanterix’ Simoa phospho-Tau 181 (pTau-181) blood test was granted Breakthrough Device designation by the U.S. FDA as an aid in diagnostic evaluation of Alzheimer’s disease. The FDA also expanded the Emergency Use Authorization (EUA) label for Quanterix’ Simoa SARS-CoV-2 N Protein Antigen Test to include testing with nasal swab and saliva samples, and for asymptomatic serial testing with nasal swab samples. The expanded label established this test as the first antigen test authorized for use with saliva samples.

“Each year the Technology Fast 500 shines a light on leading innovators in technology and this year is no exception,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In the face of innumerable challenges resulting from the pandemic, the best and brightest were able to pivot, reinvent and transform and grow. We celebrate the winning organizations and especially the talented employees driving their success.”

Quanterix’ Simoa technology and the non-profit Powering Precision Health continues to fuel important life science research and breakthroughs. To date, Simoa has been mentioned in more than 1,400 publications. Earlier this year, the technology powered the largest and most diverse global investigation of the role of plasma neurofilament light (NfL) in dementia diagnosis, published in Nature Communications. The research marks the most robust effort to date to assess the use of NfL in blood to screen for neurodegeneration as a cause of cognitive symptoms; differentiate among neurodegenerative disorders and distinguish psychiatric disorders; and derive age-related concentration cutoffs that may help to maximize plasma NfL’s usefulness in a clinical setting.

Quanterix’ Simoa HD-X technology and assays were also used to measure pTau-217 using antibodies developed by Eli Lilly and Company for its Phase 2 TRAILBLAZER-ALZ study, which was presented by Lilly at AAIC 2021. Research suggests that pTau-217, a form of the tau protein, may be a critically important biomarker for Alzheimer’s disease diagnosis. “This research shows that plasma biomarkers will continue to play an essential role in identifying neurodegeneration and measuring the value of newly approved therapies,” added Hrusovsky.

About the 2021 Deloitte Technology Fast 500™

Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa®, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

Media:
PAN Communications
Paige Romine
(321) 652-8370
pan.quanterix@pancomm.com

Investor Relations:
Stephen Hrusovsky
(774) 278-0496
shrusovsky@quanterix.com

Source: Quanterix Corporation

Print Page
Email Alerts
RSS
IR Contacts